Fig. 3: Training and validation of TSR for the detection of LNM in EUS-FNA biopsy specimens and combination of clinicopathologic characteristics from patients with PDAC. | British Journal of Cancer

Fig. 3: Training and validation of TSR for the detection of LNM in EUS-FNA biopsy specimens and combination of clinicopathologic characteristics from patients with PDAC.

From: Tumor-stroma ratio combined with PD-L1 identifies pancreatic ductal adenocarcinoma patients at risk for lymph node metastases

Fig. 3: Training and validation of TSR for the detection of LNM in EUS-FNA biopsy specimens and combination of clinicopathologic characteristics from patients with PDAC.The alternative text for this image may have been generated using AI.

a, c ROC curves of TSR for distinguishing LNM in the EUS-FNA (a) and pre-NAT EUS-FNA (c) cohorts. b, d Distribution plot of modified TSR in the EUS-FNA (b) and pre-NAT EUS-FNA (d) cohorts. eā€“h ROC curves of the TSR combining with clinicopathologic characteristics in the training (e), validation (f), EUS-FNA (g) and pre-NAT EUS-FNA (h) cohorts. EUS-FNA indicates endoscopic ultrasound fine-needle aspiration, LNM lymph node metastasis, NAT neoadjuvant therapy, TSR tumor-stroma ratio, PDAC pancreatic ductal adenocarcinoma, ROC receiver operating characteristic.

Back to article page